Miolaxin

Quick links to important sections

Miolaxin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Miolaxin

Quick Facts

Property Description
Active Ingredients Ibuprofen, Methocarbamol
Form Oral Tablet or Caplet
Pharmacological Class Analgesic and Skeletal Muscle Relaxant Combination
Common Use Symptomatic relief of acute musculoskeletal discomfort
Origin Synthetic

Defining Miolaxin: Classification and Composition

Miolaxin is a synthetic fixed-dose combination drug classified broadly as an analgesic and skeletal muscle relaxant combination. This medicine contains the two distinct active ingredients, Ibuprofen and Methocarbamol (INN), delivered together in a single oral tablet or caplet form. The dual composition means Miolaxin belongs to two major therapeutic groups: the Nonsteroidal Anti-Inflammatory Drug (NSAID) class via Ibuprofen and the Centrally-Acting Skeletal Muscle Relaxant class via Methocarbamol. The combination of these two agents is clinically recognized for its effectiveness in addressing complex pain stemming from muscle spasm.

The Dual Nature of Miolaxin's Active Components

The drug's core identity is founded on the complementary actions of its two components, differentiating it from single-agent therapies. Ibuprofen functions primarily as the NSAID component, reducing inflammation and pain signals through the inhibition of prostaglandins. Methocarbamol acts as the skeletal muscle relaxant component, whose role is to relieve the discomfort and tension associated with acute muscle spasms by acting on the central nervous system. This specific fixed-dose strategy ensures that treatment simultaneously targets both the localized tissue irritation and the resulting involuntary muscle tension, which is a unique feature of such combination preparations.

General Purpose: What Does Miolaxin Help Relieve?

The overarching purpose of Miolaxin is to provide symptomatic relief for acute painful conditions affecting the muscles and bones, such as those resulting from a strain or minor injury. By integrating the anti-inflammatory properties with the spasm-relieving effects, the medicine targets the self-perpetuating cycle of pain and muscle tension. This dual management strategy helps to ease the severe discomfort and rigidity associated with painful musculoskeletal conditions, without being intended as a cure for any underlying chronic disease.

Regulatory References

  1. NIH StatPearls

What side effects are possible with Miolaxin?

Possible side effects and safety information

The safety profile of Miolaxin reflects the combination of potential risks associated with its two active components: the Nonsteroidal Anti-Inflammatory Drug (Ibuprofen) and the centrally-acting muscle relaxant (Methocarbamol). Adverse reactions are formally classified by frequency and grouped by the physiological system affected, consistent with official regulatory documentation.


Serious Adverse Reactions and Systemic Risks

Official labeling documents a risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which may be fatal. This risk may increase with the duration of use. The Ibuprofen component is also associated with potentially fatal gastrointestinal adverse events, such as bleeding, ulceration, and perforation. Severe, sometimes fatal, skin reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have also been reported.


Common Adverse Effects and Classifications

Adverse effects commonly documented in regulatory labeling include drowsiness and dizziness, primarily due to the muscle relaxant component. Gastrointestinal disorders classified as common for the NSAID component include dyspepsia, nausea, vomiting, and abdominal pain.


Safety Constraints and Special Populations

The medicine is officially contraindicated for managing peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery and in patients with known hypersensitivity to the components or other NSAIDs. Safety statements define an increased frequency of adverse reactions in older adults, particularly the serious gastrointestinal and CNS effects. Specific considerations are also required for patients with renal or hepatic impairment, as their body may clear the components less effectively, increasing toxicity risks. The effects of the muscle relaxant may be additive when taken with other central nervous system depressants.

Overdose and Emergency Response

Overdose: What the Official Label States

Miolaxin (Methocarbamol) is associated with an overdose profile documented in official regulatory sources. The official treatment for overdose is symptomatic and supportive because there is no specific antidote available.

Immediate emergency medical help must be sought if an overdose is suspected, especially if an individual has collapsed, experienced a seizure, or has difficulty breathing.

Documented Overdose Manifestations

Official regulatory documents list a range of signs and symptoms following an overdose, which may include:

Classification Manifestations
Common Nausea, extreme drowsiness, blurred vision, hypotension
Severe Seizures, Coma, Respiratory depression, Death (reported)

Factors and Management

Official reports indicate that severe outcomes, including fatalities, are more frequently reported when Miolaxin is ingested in combination with alcohol or other Central Nervous System (CNS) depressants, such as certain psychotropic drugs.

Management procedures described in official labeling emphasize maintaining an adequate airway, monitoring vital signs and urinary output, and administering intravenous fluids as needed. The usefulness of hemodialysis for overdose management is not established.

Therapeutic Uses of Miolaxin

Miolaxin is employed to deliver supportive symptomatic relief in clinical situations where patients experience acute, distressing symptoms arising from soft tissue issues. Its combined composition makes it particularly relevant when discomfort is driven by both tissue irritation and reflex muscle response, as the combination of agents is considered relevant in contexts involving painful musculoskeletal conditions.


Easing Acute Pain and Localized Inflammation

The medication is generally applied in conditions presenting with symptoms of sudden musculoskeletal pain and inflammation, such as those resulting from recent strains, sprains, and other minor injuries. It is relevant for managing the symptom cluster involving pain and involuntary muscle spasm, which are key symptomatic drivers in conditions like acute lower back pain or a stiff neck. By addressing the painful tissue irritation, it may assist with easing the symptom load during acute episodes, providing supportive relief that helps patients cope more steadily with difficult manifestations.

“The support provided is relevant for easing symptoms that interfere with daily comfort, such as rigidity and pain.”

Addressing Involuntary Muscle Spasm and Rigidity

Miolaxin may be part of symptomatic management in conditions where pain is accompanied by involuntary muscle spasm and subsequent rigidity. It is used to ease the debilitating tension and stiffness, contributing to improved comfort and assists with maintaining a better functional capacity during periods of heightened symptoms. This effect is relevant for easing symptoms that interfere with daily comfort and supports patients during difficult episodes by easing distress.


QuickFact Block

Quick Fact: Symptomatic Support for Musculoskeletal Discomfort
Primary Focus Acute pain, muscle spasm, and inflammation
Symptom Profile Rigidity, localized pain, and muscle tension
General Benefit Supports functional stability and eases symptom load

Regulatory References

  1. NIH DailyMed overview for Methocarbamol

Eligibility and Restrictions for Use

Who Can and Cannot Use Miolaxin? (Official Eligibility)

The eligibility for Miolaxin (Methocarbamol) is strictly defined by regulatory bodies based on patient characteristics, co-morbidities, and life stages.

Contraindications

Miolaxin is absolutely contraindicated for patients with known hypersensitivity or allergy to methocarbamol or any component of the formulation. The injectable formulation has an additional contraindication for patients with known or suspected renal pathology or impairment.

Population-Specific Limitations

Population/Condition Regulatory Status
Pediatric Patients (<16 years) Safety and efficacy have not been established, except for restricted use in tetanus.
Pregnancy (Category C) Safe use is not established. Use is restricted to cases where documented benefits outweigh potential risks.
Breastfeeding Caution is advised; it is not known if the drug is excreted in human milk.
Hepatic Impairment Use requires caution due to reduced drug clearance.
Seizure History Use of the injectable form is not recommended.

Eligibility is generally established only for adults aged 16 years and older who do not have any contraindicating conditions. Additionally, use in older adults requires caution due to increased sensitivity to sedative effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The following section details clinically relevant drug interactions for this product as documented in official government regulatory information, which outlines necessary precautions or restrictions for coadministration.

Interaction Scope

Product Categories Specific Interacting Agent Notes Interaction Constraints
Central Nervous System (CNS) Depressants Alcohol, Sedatives, Hypnotics, Anxiolytics (e.g., Benzodiazepines), Opioids Coadministration with these agents may result in additive CNS depression; use is discouraged or requires extreme caution.
Anticholinergic Agents Agents like pyridostigmine bromide (used in myasthenia gravis treatment) and other anticholinergics The product may inhibit the effects of pyridostigmine. Use in patients receiving anticholinesterase agents requires caution.
Monoamine Oxidase Inhibitors (MAOIs) None specifically listed as coadministered Combinations with MAOIs are generally contraindicated due to the potential for severe adverse reactions.

Official Interaction Statements

  • Coadministration with alcohol and other CNS depressants is restricted because the combined effects can significantly increase sedation and impair physical or mental abilities. This interaction is classified as clinically significant, warranting patient caution.
  • Official labeling notes the potential for cumulative effects when combined with agents that have anticholinergic activity, which may result in an increase in associated side effects.
  • The use of this product may interfere with certain laboratory screening tests for urinary substances, specifically those involving 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Mechanism of Action

How Miolaxin Works: The Dual Mechanistic Profile

Miolaxin operates via complementary actions targeting two distinct physiological systems: peripheral inflammation and central motor reflex signaling.

Modulating Peripheral Inflammatory Signaling

Its Ibuprofen component functions as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). This molecular action intervenes in the arachidonic acid cascade, limiting the synthesis of prostaglandins at the tissue level. Decreased prostaglandin availability diminishes the sensitization of peripheral nociceptors (pain fibers), initiating a cascade that leads to the physiological consequence of diminished nociceptor sensitization and reduced inflammatory response.

Depression of Central Spinal Reflexes

The Methocarbamol component acts entirely on the Central Nervous System (CNS), focusing on the functional depression of polysynaptic reflex pathways in the brainstem and spinal cord. This mechanism decreases the overall excitability of motor neurons, thereby suppressing the hyperactive neural arc that drives and sustains involuntary muscle tension. This results in the physiological adjustment of muscle tone, suppressing the output that drives the acute, reflex-driven skeletal muscle spasm.

Dosage and Administration Information

Official Administration Guidelines

The protocol for oral administration is centered on the principle of utilizing the lowest effective dosage for the shortest duration possible, consistent with individual treatment goals.

Administration Scope Official Requirement
Route & Frequency Oral administration once daily.
Dosing (Adults) Initial and maintenance dose is 7.5 mg once daily. The dose may be increased to 15 mg once daily for additional benefit. The maximum recommended daily oral dose is 15 mg.
Dosing (Pediatric) For Juvenile Rheumatoid Arthritis: 7.5 mg once daily is recommended for children weighing 60 kg or more. Children with lower weight require a dose based on body weight (0.125 mg/kg once daily).
Timing (Meals) May be taken without regard to the timing of meals.
Dosing (Renal Impairment) Patients undergoing hemodialysis should not exceed a maximum daily dosage of 7.5 mg.
Missed Dose If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to prevent taking a double dose.

Procedural Structure Summary

The established protocol is a once-daily oral regimen. The dose is adjusted by a healthcare provider after observing the response to initial therapy to ensure the lowest effective dose is maintained. Maximum daily dose limits (15 mg for most adults, 7.5 mg for hemodialysis patients) must be observed to align with use constraints.

Recent Clinical Evidence

Research evidence / Overview of Studies for Miolaxin

Scientific literature documents that research on Miolaxin and its active components is relevant in trials assessing short-term or episodic symptom patterns associated with muscle and bone discomfort. The evidence base primarily consists of short-term Randomized Controlled Trials (RCTs) and scientific reviews, which are relevant in trials assessing short-term or episodic symptom patterns.


Evidence for Use in Acute Musculoskeletal Discomfort

The primary research for Miolaxin was studied for acute painful conditions, such as sudden non-specific low back pain or muscle strain. Researchers conducted short-term studies that enrolled adult patients experiencing pain. The main outcomes research examined included patient-reported outcomes describing perceived discomfort related to pain intensity and measurements reflecting daily functioning.

When comparing the combination treatment to a placebo (a non-active control), findings describe patterns observed in the studies over the short-term. Studies reported measurements of pain intensity and functional assessments that differed when compared to the control group. However, studies exploring short-term symptom changes were limited, and findings were mixed regarding outcomes reflecting daily functioning after extended time intervals.


Research on the Combination Strategy

The combination of the anti-inflammatory and muscle relaxant agents was evaluated in research exploring short-term symptom changes. Specific bioequivalence studies report patterns related to the absorption of both active components when delivered in the fixed-dose tablet.

This area of research indicates that the evidence quality varies across studies. There is limited information for long-term outcomes regarding whether the combination appears to result in patterns of change that are different from those observed for the individual medicines.


Areas of Research Uncertainty

A significant limitation is that the follow-up durations were limited in many of the key trials. This means that while research provides insight into short-term changes, there is limited information for long-term outcomes. Also, data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes concerning how outcomes related to physical discomfort may be observed in older adults or individuals who have other significant medical conditions.

How should Miolaxin be stored and disposed of?

Storage and Disposal of Miolaxin

Official labeling mandates specific conditions for storing Miolaxin (methocarbamol/ibuprofen) tablets to maintain product stability and efficacy. The tablets must be stored at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F). The medication must be kept protected from excess heat, moisture, and light, and the container must remain tightly closed.

Required Conditions

Condition Requirement
Temperature 20 C to 25 C
Environment Protect from heat, light, and moisture
Child Safety Keep out of the reach of children

For disposal, the FDA recommends using a drug take-back program if available. If not, unused or expired tablets should be mixed with an undesirable substance and placed in a sealed container before being thrown into the household trash; the product must not be flushed down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Miolaxin found in:

A-Z Index: